ArticleESC heart failure2023
Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction.
Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic and prognostic value of systemic immune-inflammation index for heart failure: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Postexercise immune-inflammatory improvement in type 2 diabetes is associated with baseline insulin resistance.Frontiers in endocrinology · 2025Trial
- Prognostic value of 9 immune-inflammatory markers for patients with dilated cardiomyopathy: A retrospective study.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- The Impact of Risk Factors and Comorbidities on Heart Failure in the Aging Population.International journal of molecular sciences · 2026Review
- The Effectiveness of Current Inflammatory Indices and Clinical Scores in Early Diagnosis and Predicting Long-Term Mortality in Patients with Chronic Heart Failure.Biomedicines · 2026Article
- Associations of Inflammatory Markers and Coronary Heart Disease in Different Gender Groups in Cohort NHANES 2003-2018.Cardiology research and practice · 2026Article
- Neural-immune-cardiovascular axis: from mechanistic crosstalk to therapeutic targets in cardiovascular disease.Frontiers in immunology · 2026Review
- Risk prediction for long-term cardiovascular events in patients with concurrent hypertension, HFpEF, and unstable angina: a multicenter machine learning-assisted cohort study.Frontiers in endocrinology · 2026Article
- Association between systemic immune-inflammation index(SII) and all-cause and cardiovascular mortality in heart failure patients: a single-center retrospective analysis.Frontiers in cardiovascular medicine · 2026Article
- Effects of Dapagliflozin on Novel Inflammatory Markers in Heart Failure Patients.Cardiology research and practice · 2026Article
- Correlation of Controlling Nutritional Status Score and Systemic Immune-Inflammation Index With Frailty and Prognosis in Chronic Heart Failure Patients With Atrial Fibrillation.Cardiology research and practice · 2026Article
- Systemic immune-inflammation index as a prognostic marker in heart failure with non-dialysis chronic kidney disease: a two-cohort derivation and validation study with head-to-head comparison against natriuretic peptides.Frontiers in cardiovascular medicine · 2026Article
- Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction.Journal of translational medicine · 2025Article
- Influence of systemic immunoinflammatory index on major adverse cardiovascular events in patients with coronary heart disease with heart failure as assessed by propensity score matching.European journal of medical research · 2025Article
- Prognostic impact of systemic immune inflammatory index in patients with reduced ejection fraction heart failure.BMC cardiovascular disorders · 2025Article
- Article
- Harnessing the lymphatic system.Heart failure reviews · 2025Review
- Association Between F-SIRI and Adverse Prognosis in Patients With Chronic Heart Failure.Clinical cardiology · 2025Article
- Heart failure, inflammation and exercise.International journal of biological sciences · 2025Review
- Association of Immune Nutrition Indices with the Risk of All-Cause Mortality and Cardiovascular Mortality in Patients with Heart Failure in the NHANES (1999-2018).Reviews in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
aimsWe aim to investigate the correlation between high levels of the systemic immune-inflammation index (SII) and long-term mortality and major cardiovascular adverse events in advanced chronic heart failure patients with renal dysfunction. METHODS AND
resultsSeven hundred seventeen advanced chronic heart failure patients with renal dysfunction, who visited the First affiliated hospital of Zhengzhou University from September 2019 to December 2020, were included. All-cause mortalities (ACM) were selected as primary endpoints and major cardiovascular adverse events (MACEs) as the secondary endpoints. Based on the receiver operating characteristic (ROC) curve and the Youden index, the optimal cut-off values of SII for ACM and MACEs were 1228 and 1406. In the group where ACM were the primary endpoint, patients were categorized into the low-SII group (n = 479) and the high-SII group (n = 238). Patients in the group using MACEs as the secondary endpoint were also categorized into the low-SII groups (n = 514) and the high-SII groups (n = 203). Univariate and multivariate COX regression were used to screen the independent predictors for ACM and MACEs, revealing the relationship between SII levels and endpoints. According to the univariate COX analysis, SII was the risk factor (hazard ratio [HR] = 2.144, 95% confidence interval [CI]: 1.565-2.938, P < 0.001) for the ACM subgroup. It was also the risk factor (HR = 1.625, CI: 1.261-2.905, P < 0.001) for the MACEs subgroup. Multivariate COX regression analysis indicated that the occurrence of ACM and MACEs in high-level SII and low-level SII patients had statistical differences. The incidence of ACM increased by 70.3% (HR = 1.703; 95% CI: 1.200-2.337; P = 0.002) in patients of the high SII level group, the incidence of MACEs increased by 58.3% (HR = 1.583, 95% CI: 1.213-2.065, P = 0.001). Kaplan-Meier (K-M) survival analysis further suggested that patients with a high SII level had an increased risk of having ACM (log-rank P < 0.001) and MACEs (log-rank P < 0.001) within 30 months. SII could be considered as a novel predictor of the occurrence of ACM and MACEs for patients with advanced chronic heart failure and renal dysfunction.
conclusionsThis study suggested that SII is a novel independent predictor of mortality in advanced chronic heart failure patients with renal dysfunction, and it should be considered in current clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.